SIGA Technologies, Inc. (SIGA)
After hours:
| Previous close | 8.76 |
| Open | 8.75 |
| Bid | 8.64 x 200 |
| Ask | 8.67 x 400 |
| Day's range | 8.55 - 8.83 |
| 52-week range | 4.22 - 10.00 |
| Volume | |
| Avg. volume | 799,745 |
| Market cap | 615.653M |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | 9.12 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 25 Mar 2024 |
| 1y target est | N/A |
- GlobeNewswire
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian). Effective June 1, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to maintain continuity for key c
- GlobeNewswire
SIGA Names Larry Miller General Counsel
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. “With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving
- GlobeNewswire
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
• Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In 2023, SIGA had approximately $131 million in produc
